These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35337739)

  • 1. Impairments of glutamatergic synaptic transmission in Alzheimer's disease.
    Zott B; Konnerth A
    Semin Cell Dev Biol; 2023 Apr; 139():24-34. PubMed ID: 35337739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Insights on Glutamatergic Dysfunction in Alzheimer's Disease and Therapeutic Implications.
    Pinky PD; Pfitzer JC; Senfeld J; Hong H; Bhattacharya S; Suppiramaniam V; Qureshi I; Reed MN
    Neuroscientist; 2023 Aug; 29(4):461-471. PubMed ID: 35073787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid.
    Nimmrich V; Ebert U
    Rev Neurosci; 2009; 20(1):1-12. PubMed ID: 19526730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.
    Pham E; Crews L; Ubhi K; Hansen L; Adame A; Cartier A; Salmon D; Galasko D; Michael S; Savas JN; Yates JR; Glabe C; Masliah E
    FEBS J; 2010 Jul; 277(14):3051-67. PubMed ID: 20573181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid beta peptides and glutamatergic synaptic dysregulation.
    Parameshwaran K; Dhanasekaran M; Suppiramaniam V
    Exp Neurol; 2008 Mar; 210(1):7-13. PubMed ID: 18053990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease.
    Paula-Lima AC; Brito-Moreira J; Ferreira ST
    J Neurochem; 2013 Jul; 126(2):191-202. PubMed ID: 23668663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease amyloid beta-protein and synaptic function.
    Ondrejcak T; Klyubin I; Hu NW; Barry AE; Cullen WK; Rowan MJ
    Neuromolecular Med; 2010 Mar; 12(1):13-26. PubMed ID: 19757208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures.
    Bate C; Williams A
    Neurobiol Dis; 2018 Mar; 111():48-58. PubMed ID: 29272738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic dysfunction in Alzheimer's disease.
    Marcello E; Epis R; Saraceno C; Di Luca M
    Adv Exp Med Biol; 2012; 970():573-601. PubMed ID: 22351073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex.
    Sokolow S; Luu SH; Nandy K; Miller CA; Vinters HV; Poon WW; Gylys KH
    Neurobiol Dis; 2012 Jan; 45(1):381-7. PubMed ID: 21914482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ryanodine receptor-calstabin interaction stabilizer S107 protects hippocampal neurons from GABAergic synaptic alterations induced by Abeta42 oligomers.
    Hidisoglu E; Chiantia G; Franchino C; Tomagra G; Giustetto M; Carbone E; Carabelli V; Marcantoni A
    J Physiol; 2022 Dec; 600(24):5295-5309. PubMed ID: 36284365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease.
    Rodriguez-Perdigon M; Tordera RM; Gil-Bea FJ; Gerenu G; Ramirez MJ; Solas M
    Hippocampus; 2016 Oct; 26(10):1303-12. PubMed ID: 27258819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: a model system to study neurotoxicity in Alzheimer's disease.
    Vazin T; Ball KA; Lu H; Park H; Ataeijannati Y; Head-Gordon T; Poo MM; Schaffer DV
    Neurobiol Dis; 2014 Feb; 62():62-72. PubMed ID: 24055772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies.
    Pereira C; Agostinho P; Moreira PI; Cardoso SM; Oliveira CR
    Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):383-403. PubMed ID: 16101556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAPGEF2 mediates oligomeric Aβ-induced synaptic loss and cognitive dysfunction in the 3xTg-AD mouse model of Alzheimer's disease.
    Jang YN; Jang H; Kim GH; Noh JE; Chang KA; Lee KJ
    Neuropathol Appl Neurobiol; 2021 Aug; 47(5):625-639. PubMed ID: 33345400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.
    Viola KL; Klein WL
    Acta Neuropathol; 2015 Feb; 129(2):183-206. PubMed ID: 25604547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses.
    Cerpa W; Dinamarca MC; Inestrosa NC
    Curr Alzheimer Res; 2008 Jun; 5(3):233-43. PubMed ID: 18537540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid Beta-Related Alterations to Glutamate Signaling Dynamics During Alzheimer's Disease Progression.
    Findley CA; Bartke A; Hascup KN; Hascup ER
    ASN Neuro; 2019; 11():1759091419855541. PubMed ID: 31213067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
    Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
    Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer's disease mice and correlates with memory deficits in human subjects.
    Ahmad F; Das D; Kommaddi RP; Diwakar L; Gowaikar R; Rupanagudi KV; Bennett DA; Ravindranath V
    Sci Rep; 2018 Sep; 8(1):13119. PubMed ID: 30177812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.